Healthcare
Monte Rosa Therapeutics, Inc.(GLUE)
Live Price
Offline$18.67
+1.97% today
1Y Change
+291.40%
Window
Jun 25, 2025 โ Jun 22, 2026
- Market Cap
- $1.23B
- Revenue Growth
- +63.5%
- EPS Growth
- +53.1%
- Dividend Yield
- 0.0%
Coverage: 248 bars ยท Jun 25, 2025 โ Jun 22, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Monte Rosa Therapeutics, Inc. (GLUE) is a Healthcare stock with a market cap of $1.23B and listed on NASDAQ. The stock last traded around $18.67 and up 291.4% across the available one-year price window (Jun 25, 2025 โ Jun 22, 2026). Baseline metrics include revenue growth of +63.5%, EPS growth of +53.1%, a dividend yield of 0.0%. What stands out right now is revenue +63.5%, EPS +53.1%, free cash flow -172.3% with operating margin -43.8% and ROIC -13.6%. Valuation already assumes a fairly strong business story at price/sales 10.0. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines GLUE price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+63.5% vs +7.6% peer median
Operating Margin
Below sector median
-43.8% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 14, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +63.5% and EPS at +53.1%, with operating margin around -43.8%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +1.0% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 14, 2026 | โ | -2.8% | +1.1% | -2.4% |
2026 Mar 17, 2026 | -53.6% | -1.7% | -8.2% | +13.7% |
2025 Nov 6, 2025 | +9.9% | -5.4% | +10.1% | +33.8% |
Benchmark Edge
GLUE vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
GLUE
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
GLUE Max Drawdown
-41.84%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for GLUE and SPY.
Company Overview
Monte Rosa Therapeutics, Inc.
NASDAQ Global Select
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.
- Leadership
- Markus Warmuth
- IPO Date
- Jun 24, 2021
- Employees
- 142
- Street Address
- 645 Summer Street
- Mailing
- Boston, MA, 02210
- Region
- Boston, MA, US
- Reporting Currency
- USD
- Investor Line
- 617 949 2643
- Last Updated
- Apr 29, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 10.0
- Price/Book
- 5.3
Growth
- Revenue
- +63.5%
- EPS
- +53.1%
- Free Cash Flow
- -172.3%
Profitability
- Gross Margin
- 96.6%
- Operating Margin
- -43.8%
- Net Margin
- -31.2%
- ROE
- -15.1%
- ROIC
- -13.6%
Balance Sheet
- Debt/Equity
- 0.17
- Current Ratio
- 6.12
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.